Intrathecal Drug Delivery Device Shire

We have collected information about Intrathecal Drug Delivery Device Shire for you. Follow the links to find out details on Intrathecal Drug Delivery Device Shire.


Shire's new Elaprase formulation fails late-stage trial ...

    https://www.biopharmadive.com/news/shires-new-elaprase-formulation-fails-late-stage-trial/513429/
    Dec 19, 2017 · Shire's new formulation, known as SHP609 or HGT-2310, is largely the same, only it's administered directly into a patient's cerebrospinal fluid through an intrathecal drug delivery device. After a year of monthly treatments, participants in the trial's experimental arm didn't show significant improvement in cognition compared to control groups, according to topline results released Tuesday.

A Study of Intrathecal SHP611 in Participants with Late ...

    https://www.shiretrials.com/en/studies/clinicaltrialsen/2018/12/11/10/08/shp611-201
    The study will consist of a screening period of up to 28 days. All participants will receive a once weekly dose of intrathecal (IT) SHP611 at 150 mg for 105 weeks via an intrathecal drug delivery device (IDDD) that will be implanted during a period of up to 10 days before the first administration of IT SHP611.

Shire's intrathecally delivered candidate for Hunter ...

    https://www.fiercepharma.com/drug-delivery/shire-s-intrathecally-delivered-candidate-for-hunter-syndrome-gets-fda-s-fast-track
    Jan 27, 2015 · Rare disease specialist Shire announced today that it has received Fast Track Designation from the FDA for a reformulated, intrathecally delivered version of its successful drug …

Shire ERT Enzyme Replacement Therapy Clinical Trial HGT ...

    https://mldfoundation.org/research-shire.php
    Study Summary – Every other week intrathecal injections for 38 weeks via an intrathecal drug delivery device (IDDD) or port implanted in the patient's abdomen. Cohorts – The study will be performed with 18 patients divided into three cohorts of six patients each at increasing dosages of HGT-1110; 10, 30 & 100 mg at each infusion.

Shire’s investigational SHP609, idursulfase -IT, receives ...

    https://www.shire.com/~/media/shire/shireglobal/shirecom/pdffiles/newsroom/2015/january/20150126-fast-track-press-release.pdf?la=en
    Jan 26, 2015 · fluid via an intrathecal drug delivery device * (IDDD). This formulation is being investigated and developed for use with Shire’s currently approved t reatment for Hunter syndrome, ELAPRASE® (idursulfase). ELAPRASEis administered intravenously and does not cross the blood-brain barrier in clinically relevant amounts.

Rare Diseases - Shire

    http://investors.shire.com/~/media/Files/S/Shire-IR/presentations-webcast/content-pdf/07-shire-mayer-cns.pdf
    intrathecal drug delivery device (IDDD) • Soph-A-Port ® Mini S is an implantable access system designed to provide repeated access to the intrathecal space for drug delivery • It is CE marked in Europe and approved for investigational use in the US • It is. currently being used in Shire’s Hunter-IT, Sanfilippo A and MLD

Intrathecal drug delivery in the era of nanomedicine ...

    https://www.sciencedirect.com/science/article/pii/S0169409X20300120
    Intrathecal (IT) administration, i.e., the injection of substances directly into cerebrospinal fluid (CSF) that fills the thecal sac, is a potentially powerful drug delivery approach. This route of administration can achieve a high concentration of therapeutic agent within the central nervous system (CNS) while minimizing off-target exposure ...Author: M.J. Fowler, J.D. Cotter, B.E. Knight, E.M. Sevick-Muraca, D.I. Sandberg, D.I. Sandberg, R.W. Sirian...

Shire Announces Top-Line Results for Phase II/III Clinical ...

    https://www.globenewswire.com/news-release/2017/12/19/1266050/0/en/Shire-Announces-Top-Line-Results-for-Phase-II-III-Clinical-Trial-in-Children-with-Hunter-Syndrome-and-Cognitive-Impairment.html
    Dec 19, 2017 · In clinical trials, SHP609 is administered to patients using an intrathecal drug delivery device. 7 SHP609 is administered directly into the cerebrospinal fluid as a means of delivering the drug ...Author: Shire Pharmaceuticals Group

Targeted Drug Delivery for Chronic Pain Medtronic

    https://www.medtronic.com/us-en/patients/treatments-therapies/drug-pump-chronic-pain.html
    OVERVIEW TARGETED DRUG DELIVERY. Patients report a reduction in pain scores after receiving targeted drug delivery. 51% of patients completely eliminated other opioids* at 12 months. 1 87% of patients rated their quality of life as fair to excellent. 2 90% of patients would recommend therapy to a family member or friend. 2

Searching for Intrathecal Drug Delivery Device Shire?

You can just click the links above. The data is collected for you.

Related Delivery Info